

Special Issue

Correlating Patient-Reported Quality of Life before, during, and after Therapy with Objective Measures and Outcomes

Message from the Guest Editors

The incorporation of patient-reported outcomes (PRO) and quality of life (QOL) is standard practice in modern cancer clinical trials for any combination of surgery, chemotherapy, and/or radiation therapy. While these metrics were designed to characterize the patient's experience of disease and treatment sequelae, a growing body of evidence suggests that PRO/QOL parameters can have prognostic implications. Many validated instruments are currently in use. The correlation of these instruments with objective measures (such as imaging, biomarkers, patient functioning, and survival) is necessary to identify the optimal instrument(s) for each population. In this Special Issue, we invite original manuscripts and review articles on all topics comparing PRO/QOL instruments, with an emphasis on correlations with objective measures such as imaging, biomarkers (immune function, markers of stress, etc.), patient functioning, and survival.

Guest Editors

Prof. Dr. Anurag K. Singh

Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Dr. Evan Michael Graboyes

Department of Otolaryngology–Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA

Deadline for manuscript submissions

closed (5 July 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/73049

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)